View More Recent Stories
-
Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q2 EPS
-
Piper Sandler Reiterates Overweight Rating on Allogene (ALLO)
-
Piper Sandler Reiterates Overweight Rating on Allogene (ALLO)

